Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Oliver Brendan Rooney"'
Autor:
Adam S. Kibel, Martin Gleave, Sabine D. Brookman-May, Won Kim, Christopher P. Evans, Eleni Efstathiou, Philip W. Kantoff, Ashley Ross, Neal D. Shore, Alberto Briganti, Boris A. Hadaschik, Axel Heidenreich, Oliver Brendan Rooney, Shaozhou Ken Tian, Lisa Wetherhold, Weichun Xu, J. Kellogg Parsons, Kesav Yeruva, Mary-Ellen Taplin
TPS285 Background: In pts with localized high-risk PC, disease recurrence rate following RP is ̃50% (Kane et al. J Urol. 2007). Treatment (tx) with androgen blockade before RP can reduce tumor burden post RP (Taplin et al. J Clin Oncol. 2014; McKay
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a7471f5ec855334535368386ed3ab903
Autor:
Fred Saad, Susan Li, Oliver Brendan Rooney, Sabine Brookman-May, Hiroji Uemura, Boris Hadaschik, Eric J. Small, Matthew R. Smith, Paul N. Mainwaring, Julie N. Graff, Simon Chowdhury, Ke Zhang, Stéphane Oudard, Andressa Smith, David Olmos, Peter De Porre, Ji Youl Lee, Angela Lopez-Gitlitz
5516 Background: SPARTAN evaluated APA vs PBO in pts with nmCRPC and a prostate-specific antigen doubling time of ≤ 10 mo receiving androgen deprivation therapy (ADT). At primary end point analysis of metastasis-free survival (MFS), APA significant
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b5643edc72d9fe430a71e244ceb088f3
Autor:
Kim N. Chi, Axel S. Merseburger, Mustafa Ozguroglu, Simon Chowdhury, Anders Bjartell, Byung Chung, Andrea Juliana Pereira de Santana Gomes, Robert Given, Álvaro Juárez, Hirotsugu Uemura, Dingwei Ye, Lawrence Ivan Karsh, Benjamin Adam Gartrell, Sabine D. Brookman-May, Suneel Mundle, Sharon Anne McCarthy, Florence Lefresne, Oliver Brendan Rooney, Amitabha Bhaumik, Neeraj Agarwal
Publikováno v:
Journal of Clinical Oncology. 40:89-89
89 Background: Addition of androgen receptor signaling inhibitors to ADT + DOC has been shown to improve clinical outcomes in pts with mCSPC. TITAN, a placebo-controlled phase 3 study, showed that APA + ADT improved overall survival (OS) and other cl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::52e744de24726b1d85027d4212431011
https://doi.org/10.1200/jco.2022.40.6_suppl.089
https://doi.org/10.1200/jco.2022.40.6_suppl.089
Autor:
Oliver Brendan Rooney, Paul N. Mainwaring, Felix Y. Feng, David Olmos, Nick Fishbane, Deborah Ricci, Fred Saad, Elai Davicioni, Shibu Thomas, Michael Gormley, Simon Chowdhury, Shinta Cheng, Angela Lopez-Gitlitz, Boris Hadaschik, Matthew R. Smith, Eric J. Small, Margaret K. Yu, Yang Liu
Publikováno v:
Journal of Urology. 201
INTRODUCTION AND OBJECTIVES:The DECIPHER prostate test (GenomeDx Biosciences, Inc., San Diego, CA) is a clinical-grade mRNA-based test with a genomic classifier (GC) score that has been independent...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dcd0bee6942c297c51a7759451bd3af1
https://doi.org/10.1097/01.ju.0000555359.59547.3e
https://doi.org/10.1097/01.ju.0000555359.59547.3e
Autor:
Oliver Brendan Rooney, Nicholas Fishbane, Paul N. Mainwaring, Angela Lopez-Gitlitz, Felix Y. Feng, Fred Saad, Boris Hadaschik, Shibu Thomas, Michael Gormley, Deborah Ricci, Matthew R. Smith, Margaret K. Yu, Yang Liu, Simon Chowdhury, Shinta Cheng, David Olmos, Elai Davicioni, Eric J. Small
42 Background: The SPARTAN trial recently demonstrated that addition of APA to androgen deprivation therapy (ADT) improved metastasis-free survival (MFS) and second progression-free survival (PFS2) in nmCRPC pts. We performed transcriptome-wide profi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::687410aa2ff5efc506b9ba63095b78c6
Autor:
Oliver Brendan Rooney, Boris Hadaschik, Eric J. Small, Byron M. Espina, David Olmos, Matthew R. Smith, Shinta Cheng, Wayne R. Rackoff, Fred Saad, Anil Londhe, Paul N. Mainwaring, Julie N. Graff, Stéphane Oudard, Hiroji Uemura, Simon Chowdhury, Youyi Shu, Angela Lopez-Gitlitz, Ji Youl Lee
144 Background: In the phase 3 SPARTAN study, compared with placebo (PBO), APA, a next-generation androgen receptor inhibitor, decreased the risk of distant metastasis or death by 72% (hazard ratio [HR], 0.28; p < 0.0001) in men with high-risk nmCRPC
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3895b0d27022b280f94574d5b68271ab
Autor:
Fred Saad, Oliver Brendan Rooney, Amitabha Bhaumik, Anil Londhe, Matthew R. Smith, Paul N. Mainwaring, Eric J. Small, Ji Youl Lee, Julie N. Graff, Stéphane Oudard, Boris Hadaschik, David Olmos, Hiroji Uemura, Angela Lopez-Gitlitz
5024 Background: SPARTAN, a randomized phase 3 placebo (PBO)-controlled study in pts with high-risk nmCRPC and PSA doubling time ≤ 10 mo, showed that, compared with PBO, addition of APA to ongoing ADT treatment (tx) prolonged metastasis-free surviv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ad4542d1ba3d52f264533c7387ccf3e7
Autor:
Mary-Ellen Taplin, Martin Gleave, Christopher P. Evans, Eleni Efstathiou, Philip W. Kantoff, Ashley Ross, Neal D. Shore, Alberto Briganti, Boris A. Hadaschik, Axel Heidenreich, Oliver Brendan Rooney, Shaozhou Ken Tian, Lisa Wetherhold, Weichun Xu, Shinta Cheng, Adam S. Kibel
TPS5100 Background: Patients (pts) with localized high-risk PC experience disease progression rates of approximately 50% after RP (Kane et al. J Urol. 2007). With the approval of next-generation androgen receptor inhibitors, neoadjuvant studies have
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2055af4a9337c3327b3c09e7e221ce47
Autor:
Lisa Wetherhold, Leo Grady, Shaozhou Ken Tian, Andressa Smith, Ran Godrich, Patricia Raciti, Jeremy D. Kunz, Rodrigo Ceballos, Carla Leibowitz, Angela Lopez-Gitlitz, Sabine Brookman-May, John Alvarez, Thomas J. Fuchs, Christopher Kanan, Belma Dogdas, Sharon Anne McCarthy, Adam Casson, Oliver Brendan Rooney
Publikováno v:
Journal of Clinical Oncology. 38:e14052-e14052
e14052 Background: The need for accurate pathological identification and quantitation of prostate cancer (PC) following neoadjuvant treatment with androgen deprivation therapy (ADT) and androgen receptor antagonists is increasing as PC treatment cont
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6f763fd751f136752e3aa7eaa512eead
https://doi.org/10.1200/jco.2020.38.15_suppl.e14052
https://doi.org/10.1200/jco.2020.38.15_suppl.e14052
Autor:
Philip W. Kantoff, Weichun Xu, Neal D. Shore, Adam S. Kibel, Martin E. Gleave, Ashley E. Ross, Boris Hadaschik, Lisa Wetherhold, Oliver Brendan Rooney, Angela Lopez-Gitlitz, Shaozhou Ken Tian, Eleni Efstathiou, Christopher P. Evans, Axel Heidenreich, Alberto Briganti, Sabine Brookman-May, Mary-Ellen Taplin, Shinta Cheng
Publikováno v:
Journal of Clinical Oncology. 38:TPS383-TPS383
TPS383 Background: Patients (pts) with localized high-risk PC have disease progression rates of ~50% after RP (Kane et al. J Urol. 2007). Neoadjuvant studies show that androgen blockade can improve local disease control at the time of RP (McKay et al
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4be71a39d6cb13cffea5b065436a9cc4
https://doi.org/10.1200/jco.2020.38.6_suppl.tps383
https://doi.org/10.1200/jco.2020.38.6_suppl.tps383